CN104721214A - Lincomycin hydrochloride and pyrantel tartrate-containing compound pet tablet and preparation method thereof - Google Patents
Lincomycin hydrochloride and pyrantel tartrate-containing compound pet tablet and preparation method thereof Download PDFInfo
- Publication number
- CN104721214A CN104721214A CN201310707300.9A CN201310707300A CN104721214A CN 104721214 A CN104721214 A CN 104721214A CN 201310707300 A CN201310707300 A CN 201310707300A CN 104721214 A CN104721214 A CN 104721214A
- Authority
- CN
- China
- Prior art keywords
- tablet
- lincomycin
- pyrantel tartrate
- pyrantel
- hydrochloric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention belongs to veterinary medicine and preparing method technical field, and in particular relates to a lincomycin hydrochloride and pyrantel tartrate-containing compound tablet and a preparation method thereof, the tablet preparation comprises (a) lincomycin hydrochloride and pyrantel tartrate as raw material medicines, (b) an adhesive, (c) a wetting agent, (d) a disintegrating agent, (e) a filler and (f) a sweetener. The lincomycin hydrochloride and pyrantel tartrate-containing compound tablet is prepared by a wet process, and is a white-like tablet in character. The lincomycin hydrochloride and pyrantel tartrate-containing compound tablet is good in stability and good in palatability, and can be used a veterinary oral preparation.
Description
Technical field
The invention belongs to veterinary drug and preparation method technical field, be specifically related to the preparation method of a kind of lincomycin hydrochloride, pyrantel tartrate tablet.
Technical background
Pyrantel is all a kind of Depolarizing neuromuscular blocker to parasitic nematode and vertebrate host.Polypide paralysis caused by medicine is caused by polypide muscle contraction, and it and acetylcholine impel the effect of muscle contraction similar.Though the muscular contraction caused by pyrantel, morantel is slower than acetylcholine, act on stronger than acetylcholine 100 times.The above-mentioned effect that it should be noted that acetylcholine is reversible, and pyrantel and morantel are irreversible.
Pyrantel is similar with diethylcarbamazine citrate to the pharmacological action of host and morantel, levamisole, all has the biological characteristics of acetylcholine.These medicines Main Function and neurotransmitter in body---the effect produced when acetylcholine is excessive is identical, make chemoreceptor and the Neuromuscular inner contact of vegetative ganglia, adrenal medulla, carotid body and aortic body exactly, first excited rear paralysis, similar with nicotinic action.
Lincomycin hydrochloride, pyrantel tartrate are utilized wet preparation method by prominent features of the present invention exactly, are prepared into oral tablet for animals.The lincomycin hydrochloride prepared by this method, pyrantel tartrate tablet stability are good, good palatability, the assimilation effect that tool is good, for China's veterinary clinic utilize lincomycin hydrochloride better, pyrantel tartrate provides a kind of new preparation.
Summary of the invention
The object of the invention is to develop a kind of lincomycin hydrochloride, pyrantel tartrate oral tablet, heighten the effect of a treatment, improve stability and the palatability of medicine, tool long-acting.
The present invention, for achieving the above object, provides the water tablet of a kind of hydrochloric lincomycin, pyrantel tartrate, it is characterized in that preparation specifically consists of:
(a) lincomycin hydrochloride, pyrantel tartrate crude drug 5-20% (W/W);
(b) binding agent 10-30% (W/W);
(c) wetting agent 5-20% (W/W);
(d) disintegrating agent 20-50% (W/W);
(e) filler 20-30% (W/W);
(f) sweeting agent 2-3% (W/W);
Described a kind of hydrochloric lincomycin, the tablet of pyrantel tartrate, it is characterized in that disintegrating agent be selected from replace hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl starch sodium, PVPP, cCMC-Na, cross-linked carboxymethyl cellulose are received, cross linked polyvinyl pyrrolidone, microcrystalline Cellulose one or more;
Described a kind of lincomycin hydrochloride, the tablet of pyrantel tartrate, it is characterized in that described filler be selected from lactose, amylum pregelatinisatum, dextrin, microcrystalline Cellulose one or more.
Described a kind of hydrochloric lincomycin, the tablet of pyrantel tartrate, it is characterized in that described binding agent be selected from polyvidone (PVP), HPMC, PVP, methylcellulose, sodium carboxymethyl cellulose one or more.
Described a kind of hydrochloric lincomycin, the tablet of pyrantel tartrate, it is characterized in that described lubricant be selected from magnesium stearate, micropowder silica gel, talcous one or more.
Described a kind of hydrochloric lincomycin, the tablet of pyrantel tartrate, is characterized in that one or more that described sweeting agent is selected from aspartame, stevioside, protein sugar.
Described a kind of hydrochloric lincomycin, the tablet of pyrantel tartrate, when it is characterized in that granulating, the granularity of granule should control at 30 orders once.
Described a kind of hydrochloric lincomycin, the tablet of pyrantel tartrate, is characterized in that preparation method is as follows:
Measure all stock and adjuncts according to prescription, cross 30-120 mesh sieve; Wherein disintegrating agent and filler respectively in add and Extra Section, the ratio 1-4:1 of Nei Jia and Extra Section, weight ratio; Inside add and weigh respectively with Extra Section, and carry out labelling; By lincomycin hydrochloride, pyrantel tartrate raw material and all in add adjuvant and put mix homogeneously in mixer altogether; Add binding agent, continue mixing, make soft material, 30 mesh sieves are granulated; By granule after 50 ° of C-55 ° of C are dried, 30 mesh sieve granulate.
Detailed description of the invention
Be explained the present invention with example below, but example does not limit the scope of the invention, scope of the present invention and core content are determined according to claims.
Example: 10% lincomycin hydrochloride, pyrantel tartrate water tablet
[prescription] lincomycin hydrochloride, pyrantel tartrate 5+10% (W/W)
Microcrystalline Cellulose 20% (W/W)
PVP 15% (W/W)
Lactose 30% (W/W)
Aluminium stearate 10% (W/W)
Aspartame 15% (W/W)
[preparation]
Get prescription to measure lincomycin hydrochloride, pyrantel tartrate and above-mentioned various adjuvant and prepare according to aforementioned preparation process, i.e. obtained lincomycin hydrochloride, pyrantel tartrate water tablet.
Claims (7)
1. a tablet for hydrochloric lincomycin, pyrantel tartrate, is characterized in that preparation specifically consists of:
(a) lincomycin hydrochloride, pyrantel tartrate crude drug 5-20% (W/W);
(b) binding agent 10-30% (W/W);
(c) wetting agent 5-20% (W/W);
(d) disintegrating agent 20-50% (W/W);
(e) filler 20-30% (W/W);
(f) sweeting agent 2-3% (W/W).
2. by the tablet of a kind of hydrochloric lincomycin according to claim 1, pyrantel tartrate, it is characterized in that disintegrating agent be selected from replace hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl starch sodium, PVPP, cCMC-Na, cross-linked carboxymethyl cellulose are received, cross linked polyvinyl pyrrolidone, microcrystalline Cellulose one or more.
3. by a kind of lincomycin hydrochloride according to claim 1, pyrantel tartrate tablet, it is characterized in that described filler be selected from lactose, amylum pregelatinisatum, dextrin, microcrystalline Cellulose one or more.
4. by a kind of hydrochloric lincomycin according to claim 1, pyrantel tartrate tablet, it is characterized in that described binding agent be selected from polyvidone (PVP), HPMC, PVP, methylcellulose, sodium carboxymethyl cellulose one or more.
5. by a kind of hydrochloric lincomycin according to claim 1, pyrantel tartrate tablet, it is characterized in that described lubricant be selected from magnesium stearate, micropowder silica gel, talcous one or more.
6., by the tablet of a kind of hydrochloric lincomycin according to claim 1, pyrantel tartrate, it is characterized in that one or more that described sweeting agent is selected from aspartame, stevioside, protein sugar.
7., by the tablet of a kind of hydrochloric lincomycin according to claim 1, pyrantel tartrate, when it is characterized in that granulating, the granularity of granule should control at 30 orders once.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310707300.9A CN104721214A (en) | 2013-12-20 | 2013-12-20 | Lincomycin hydrochloride and pyrantel tartrate-containing compound pet tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310707300.9A CN104721214A (en) | 2013-12-20 | 2013-12-20 | Lincomycin hydrochloride and pyrantel tartrate-containing compound pet tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104721214A true CN104721214A (en) | 2015-06-24 |
Family
ID=53446013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310707300.9A Pending CN104721214A (en) | 2013-12-20 | 2013-12-20 | Lincomycin hydrochloride and pyrantel tartrate-containing compound pet tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104721214A (en) |
-
2013
- 2013-12-20 CN CN201310707300.9A patent/CN104721214A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102349874B (en) | Imatinib mesylate composition and preparation method thereof | |
| CN101658505A (en) | Sustained-release preparation of uloric and preparation method thereof | |
| CN106389360A (en) | Directly-compressed tablet of dapoxetine hydrochloride and preparation method thereof | |
| CN103751139A (en) | Lurasidone orally disintegrating tablet | |
| CN104814937A (en) | Topiroxostat tablet | |
| CN101401810A (en) | Dispersible tablet containing Cefixime and preparation method thereof | |
| CN103142494A (en) | Ornidazole oral preparation and preparation method thereof | |
| CN104510719A (en) | Acotiamide tablet and preparation method thereof | |
| CN104337822A (en) | Compound tablets containing mebendazole and dipterex and used for deworming on pets, and preparation method thereof | |
| CN104721214A (en) | Lincomycin hydrochloride and pyrantel tartrate-containing compound pet tablet and preparation method thereof | |
| CN102697778B (en) | Valsartan amlodipine compound solid preparation and preparation method thereof | |
| CN105456209A (en) | Topiroxostat tablet and preparation method thereof | |
| CN104274415A (en) | Atipamezole hydrochloride-containing calming and pain easing tablet for pets, and preparation method thereof | |
| CN103393611A (en) | Ivabradine hydrochloride tablet and preparation method thereof | |
| CN104337776A (en) | Tablets containing diclofenac sodium and having analgesic effect on pets, and preparation method thereof | |
| MY169160A (en) | Method for producing starch granules, and orally disintegrating tablet | |
| CN102552197A (en) | Tablet containing febuxostat and preparation method of the tablet | |
| WO2007026261A3 (en) | Formulations containing losartan and/or its salts | |
| CN109481437B (en) | Losartan potassium pharmaceutical preparation | |
| CN104338113A (en) | Amfomycin calcium + hydrocortisone + kanamycin sulfate compound tablet for infection prevention of pets, and its preparation method | |
| CN104337777A (en) | Tablets containing ketoprofen and having analgesic effect on pets, and preparation method thereof | |
| CN104274475A (en) | Gentamicin sulfate and betamethasone valerate containing compound tablet for treating skin infection of dogs | |
| CN104337815A (en) | Zolazepam hydrochloride and tiletamine hydrochloride-containing compound tablet for easing pains of pets, and its preparation method | |
| CN101305986A (en) | Lafutidine Tablet and its preparation method | |
| CN106667929A (en) | Asenapine tablets and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150624 |